Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

InnaVirVax Strengthens Patent Protection of VAC-3S Immunotherapy

Published: Wednesday, December 26, 2012
Last Updated: Wednesday, December 26, 2012
Bookmark and Share
The Company reaches a new stage of development with the filing of a new European patent application for VAC-3S aimed at protecting the immune system of patients infected with HIV-1.

InnaVirVax has announced that a new European patent application has been filed on VAC-3S, a (first-in-class) immunotherapy for the treatment of HIV infections.

This patent application claims the use of new immunogenic compositions that are optimized to induce a strong immune response in humans. It also relates to use of such immune compositions with enhanced properties compared to references.

This industrial property consolidation is based on the research undertaken by the Company since its inception, more than 3 years ago. It deals with an essential stake showing InnaVirVax’s ability to create value through innovation and patents.

Joël Crouzet, CEO of InnaVirVax declared: “For more than 3 years, InnaVirVax has had a proactive policy of construction and protection of its intellectual property by intensifying its international patents coverage. After the two patent applications filed last year on our DIAG-3S prognostic test and on an innovating vaccine, this new patent application protects our therapeutic vaccine currently under development. This corresponds to our will to build a strong and long-lasting scientific and medical project portfolio, the key of our future business successes”.

InnaVirVax is developing VAC-3S from a patent family covering Europe, the United States, Canada and China whose property belongs to Inserm and the AP-HP.

InnaVirVax has been granted an exclusive worldwide license since May 2009.

This immunotherapy is currently under phase I/IIa clinical development. The clinical trial is being conducted since February 2012 in two major clinical reference centers in Paris: the Pitié Salpêtrière and Cochin Hospitals. It involves 24 patients infected with HIV-1 whose viral load is controlled under antiretroviral therapy.

The primary endpoint is the safety of this immunotherapy. The immunogenicity of the candidate drug is also being studied, as are its effects on markers of HIV infection (notably the CD4 count, viral load and markers of cellular activation).

Patients are being immunized and then followed for one year. This clinical trial has been awarded a grant of €600,000 from OSEO, the French government-backed agency that supports innovation.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Successful Completion of Phase I/IIa Clinical Study of VAC-3S Immunotherapeutic Vaccine
Interim results of the phase I/IIa clinical study revealed a good safety and tolerability profile for the VAC-3S immunotherapeutic vaccine, which was the primary endpoint of the study performed in two AP-HP reference clinical centers in Paris, France, at Pitié Salpêtrière and Cochin Hospitals.
Monday, December 03, 2012
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos